Popular diet slashes liver fat by 67% while reversing prediabetes in some people

People battling fatty liver disease and prediabetes could see a dramatic shift in health outcomes if a popular low‑carb regimen delivers on recent findings. Reports describe a rapid decline in liver fat and, for some, a complete reversal of prediabetes, promising fewer medical interventions and lower long‑term disease risk. The potential gain targets patients struggling with metabolic dysfunction who face costly treatments and quality‑of‑life impacts. Clinicians and insurers alike are watching the data for signs of cost savings. The diet at the center of the discussion is the ketogenic regimen, a high‑fat, very low‑carbohydrate plan that forces the body into ketosis.

By shifting fuel use from glucose to fat, the approach is said to lower hepatic lipid accumulation. Nutrition experts note that this metabolic switch differentiates keto from more balanced eating patterns such as the Mediterranean diet, which has traditionally been recommended for heart health. Proponents argue the sustained ketone production also supports insulin sensitivity. Recent peer‑reviewed research cited by EatingWell and EMJ spotlights metabolic benefits that extend beyond simple weight loss, noting a pronounced drop in liver fat. The same study, noted by ConsumerAffairs, observed a 67% reduction in hepatic fat and reversal of prediabetes in a subset of participants.

Fox News amplified these results, calling the diet “popular” and emphasizing the potential clinical impact. The coverage collectively points to a reproducible effect under controlled conditions. The next step will be longer‑term trials that track liver health and glucose regulation over years, as current reports focus on short‑term outcomes. Researchers will need to confirm whether the liver‑fat loss sustains and if prediabetes reversal holds across larger, diverse populations. Observers will be watching for FDA guidance or clinical‑practice updates that could integrate keto protocols into standard metabolic‑disease management.